MedTrace Logo

IRONCARE: Iron Treatment in Older Patients With Hip Fractures

NCT07659184 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 528

Last updated 2026-06-24

No results posted yet for this study

Summary

The aim of this study is to investigate the effects of intravenous (IV) iron therapy compared to alternate-day oral iron treatment and no supplementation in older patients with hip fractures. This study will examine the impact of iron treatment on fatigue, functional decline, fear of falling, cognitive impairment, and quality of life, as well as its effects on iron stores and hemoglobin levels, with the overall goal of improving postoperative rehabilitation.

The trial will be conducted on five different hospitals in the Central Region of Denmark (Region Midtjylland).

Conditions

  • Hip Fracture
  • Anemia
  • Iron
  • Placebo - Control

Interventions

DRUG

Ferric Derisomaltose

Intravenous Ferric Derisomaltose shortly after surgery and placebo tablets on alternate days for 90 days

DRUG

Oral Iron (Ferrous sulphate)

Oral iron sulfate on alternate days for 90 days and IV placebo once shortly after surgery

DRUG

Placebo IV

100 ml Sodium Chloride (NaCl)

DRUG

Placebo Tablets

Placebo tablets on alternate days for 90 days

Sponsors & Collaborators

  • Region MidtJylland Denmark

    collaborator OTHER

  • Viborg Regional Hospital

    collaborator OTHER

  • Gødstrup Hospital

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Randers Regional Hospital

    collaborator OTHER

  • Regionshospitalet Horsens

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07659184 on ClinicalTrials.gov